Filing Flows › ARS Pharmaceuticals (SPRY) › Q1 2025
ARS Pharmaceuticals (SPRY) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
ARS Pharmaceuticals (SPRY) reported revenue of $8.0M for the first quarter 2025 (Q1 2025) and -91% from the quarter before. Operating margin was -466.3%, net loss $33.9M (425.7% of revenue).
ARS Pharmaceuticals, Q1 2025: revenue $8.0M, operating margin -466.3%, net loss $33.9M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.0M | -91% | — |
| Operating profit | −$37.2M | — | — |
| Net earnings | −$33.9M | — | — |
| Operating cash flow | −$40.7M | — | — |
What changed
Revenue was $8.0M in Q1 2025, down 91% from the previous quarter. Product was the largest line at 97% of revenue.
Operating costs exceeded revenue by $37.2M, an operating margin of -466.3%. The quarter ended with a net loss of $33.9M, after a profit of $49.9M the previous quarter.
Operating cash flow was −$40.7M. Non-cash charges added back $280K of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items used $12.4M. Capital expenditures of $91K exceeded it, leaving free cash flow of −$40.8M.
Questions
What was ARS Pharmaceuticals' revenue in the first quarter 2025?
ARS Pharmaceuticals (SPRY) reported revenue of $8.0M for the first quarter 2025 (Q1 2025) and -91% from the quarter before.
Was ARS Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $37.2M (-466.3% of revenue) and net loss $33.9M.